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The benefits of deep brain stimulation for parkinsonian patients are well documented and have
established the method as mainstay in the late stages of the disease (Deuschl et al., 2006). However,
early in the history of the method reports of mental side effects were published. In 1995 Limousin
and colleagues reported transient confusion and hallucinations with one of their first patients
(Limousin et al., 1995). Further reports with disturbing side effects accumulated over time (Krack
et al., 2001; Berney et al., 2002; Herzog et al., 2003a). While cognitive squeals were studied in
numerous papers (Funkiewiez et al., 2004; Contarino et al., 2007) but are generally conceived to
have little impact on the quality of life (Schupbach et al., 2006), the field of psychiatric effects was
more hesitantly explored. Results to the latter remain ambiguous with a tendency toward less severe
side effects in the large series of experienced centers (Deuschl et al., 2006; Weaver et al., 2009).
Adverse events in this domain were largely attributed to acute effects weaning over a short period
(Herzog et al., 2003b).
However, over the years I have seen a considerable number of patients both operated by myself
but also from other experienced centers who showed psychological symptoms that counteracted
the improvements in motor function. This personal experience is in line with patients and
their representatives who voice concern over these phenomena with their deleterious impact
on the wellbeing of patients, their families and caregivers (personal communication, F-W.
Mehrhoff, Geschäftsführer, Deutsche Parkinsonvereinigung, Nov. 2014). Such concerns also appear
quite regularly in patient support group meetings. My impression is, that patients and their
representatives feel their concerns not appropriately reflected in the scientific literature and expert
opinions. This comment responds to such observations with the aim to reposition the defense of
DBS for Parkinson’s disease. Reluctance to delve into this subject may in my opinion eventually
leave those who offer the procedure defenseless toward reproach from patients, referring colleagues
and the general public.
Onemay counter such observations by outlining that, particularly in case of complex psychiatric
side effects, there are no objective means of deciding when a treatment has to be considered a failure
or a success. Patients and relatives have also the propensity to underestimate their preoperative
disabilities (Herzog et al., 2003b). This is further complicated by the fact that PD is a disease with
cognitive, affective, and behavioral symptoms and thus has a neuropsychiatric impact on the patient
as well. DBSmay even in some cases restore the original personality, which then is simply not fitting
any more into the actual social and familial setting. Finally, also medication-based therapies for PD
can have severe neuropsychiatric effects (Cools et al., 2003).
Nevertheless, there remains a substantial proportion of DBS patients with severe and lasting
behavior disturbances, which were credibly not present in the ultimate preoperative phase and that
also has led to critical comments in the literature (Moro, 2009). These comprise reckless driving
or other forms of risk-seeking behavior and even aggressive and contemptuous behavior toward
Abbreviations: DBS, Deep brain stimulation; GPI, Globus pallidus internus; STN, Subthalamic nucleus.
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relatives and spouses. In some cases this can be remedied by
moving the active contacts outside the STN with subsidence of
aggressive behavior within hours. This hints to a direct effect
of stimulation. Unfortunately in some patients stimulation must
be markedly reduced or switched off completely to ameliorate
psychiatric effects. Numerous reports and case series have
contributed to this issue with delineation of alarming psychiatric
disturbances ranging from hypomania to suicidal ideation and
suicide (Herzog et al., 2003a; Morgan et al., 2006; Schupbach
et al., 2006; Witt et al., 2008). At the same time other publications
failed to find relevant changes of personality and behavior
(Schuepbach et al., 2013), considered significant changes as not
relevant for overall quality of life (Morgan et al., 2006) or even
found much higher incidence of psychoses in the control group
compared to the DBS group. I will now elaborate on these issues
in some more detail.
MOOD AND BEHAVIOR
A symptom that may be systematically underestimated in its
frequency is hypomania. It occurs early after the intervention
and may lead to apparent improvement in rating scales like
the Beck Depression Inventory and scales measuring quality
of life. The subjective rating by the patient may however be
a result of direct stimulation of the limbic system and not a
normal joyful response to the improved motor performance.
Hypomania becomes dangerous though impaired judgment of
the own abilities and limits. While the patient (and the surgeon)
may be content or even happy with the result, the patient’s family
may be dismayed about disinhibited and reckless behavior.
After some weeks hypomania may subside but other
alterations in mood and behavior surface. Depression and
Apathy may evolve and stay for years leading to markedly
reduced quality of life not only for the patient but also for his
caregivers. The reasons for both remain unclear and have been
attributed to the stimulation directly or the resulting changes
in medication. The incidence of both is relatively well reflected
in the scientific literature (Drapier et al., 2006) with a minority
finding contradicting results. With few exceptions the burden
resulting from altered mood and behavior on caregivers and
families has not received much attention (Lewis et al., 2015).
SUICIDE
While some studies found markedly elevated incidences of
suicide (Voon et al., 2008) a direct association with DBS surgery
was not found in a recent prospective study (Weintraub et al.,
2013). This may indicate improvements regarding selection
criteria—but the observation time in latter study was however
short and patients were in the close scrutiny of a prospective
setting allowing early detection and intervention if suicidal
ideation occurred. The issue is further complicated by the fact
that suicide after DBS has occurred not only with different
anatomic targets but also with other diseases than Parkinson’s
disease (Appleby et al., 2007). Rare events like suicide are
statistically difficult to assess, however, it is alarming that even in
prospective studies with close monitoring of patients these events
occur (Schuepbach et al., 2013). From a laymen’s viewpoint the
situation remains confusing; patients and their relatives remain
worried due to reports of such events in patient representative
organizations that seem to be in contrast to studies and expert
opinions. To my understanding, a definite proof of the safety of
the procedure in this respect is at present not available and the
matter may eventually only be solved by a comprehensive DBS
case registry.
MORAL COMPETENCE AND
PERSONALITY
These are (in my view) the issues with the most confounding
ethical impact. While hypomania subsides and depression may
respond to treatment, rarely measurements are taken to exclude
less obvious changes in behavior and personality. Fundamental
changes in personality have been relatively seldom been studied
(Florin et al., 2013) although basic research documents the role of
the STN in decision making (Ray et al., 2011). Relatives however
report reckless and risk seeking behavior that lasts well beyond
the postoperative phase. Again, these types of behavioral change
may occur gradually in the natural course of the disease or as
side effect of drugs—but the sudden and seemingly irreversible
alteration of personally after DBS comes as a shock for families.
Probably the most profound, albeit at first sight easily overlooked
effects are changes in moral competences of the patients. Such
changes may result in taking risks for oneself and ignoring the
rights of others, exemplified by car accidents or marital conflicts
(Schupbach et al., 2006). Seminars for management of such
conflicts after DBS are therefore already offered with patients and
spouses reporting their experiences.
Changes in personality or moral competences have so far
not been an issue in recent large studies (Schuepbach et al.,
2013). One reason might be that they are difficult to measure
with the scales presently at hand. Scales using the patient’s own
perception are fated to miss deficits in his ability to cope with
the needs of others. Recently, the issue has come into focus
(Fumagalli et al., 2015), but more appropriate scales to detect
and quantify such complex changes must be implemented in the
future (Witt et al., 2013). Cooperation with specialists in the area
of moral psychology should be considered to adopt scales and
knowledge.
THE STN AS TARGET
One reason for the frequency of psychiatric side effects may be
the stimulated target. As the standard target for DBS in Parkinson
disease the STN must be foremost scrutinized.
One of the basic assumptions in defense of the safety of
the STN is the assumption that it consists of three clearly
separated parts and that electrodes can be reliably steered
into the motor part that exclusively contains motor functions.
This concept while propagated by some researchers (Temel
et al., 2005) has at the same time been questioned by others
(Keuken et al., 2012). Furthermore, with the assumed motor
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division being quite small currents from the presently used
electrodes will almost inevitably spread to other parts namely
the limbic subdivision (taking into account that currents spread
sideways from the electrode into areas outside the intended
target).
Empirically the majority of studies come to the conclusion
that targeting the GPI produces less psychiatric side effects (Liu
et al., 2014) while allowing for almost equal motor improvement.
Only one recent study found a clear advantage for the STN
(Odekerken et al., 2013). Disadvantages of GPI are a smaller
reduction of medication and possibly a weaning of effect over
time. The necessity to keep up a high level of dopaminergic
medication may itself provoke psychiatric events (Volkmann
et al., 2004). Still the GPI may serve as target for a subset of
patients prone to complications by STN-stimulation as outlined
in a recent comment (Krack and Hariz, 2013). As such it
has been advertised as target for patients prone to psychiatric
complications1.
The evaluation search for alternative targets should therefore
be continued. Other promising targets are located in the
subthalamic space within the fiber connections between thalamus
cerebellum and basal ganglia as proposed by Velasco and others.
However, it must been kept in mind that the basal ganglia and
the cerebellum are involved in the processing of cognitive and
emotional tasks and with the effects of stimulation spreading
far complete avoidance of mental side effects is therefore not
possible.
PERSPECTIVES
In summary, the available evidence suggests tomy understanding
that neuropsychiatric effects may be an integral albeit unintended
effect of DBS for Parkinson’s diseases. The ethical issues related
to these effects may be even less trivial compared with DBS
for psychiatric disorders. In the latter case, DBS is used with a
transparent and obvious intention to interfere with the patient’s
psyche (Chabardes et al., 2013). In DBS for Parkinson’s disease,
the neuropsychiatric effects are not an obvious “part of the deal”
with the patient.
Subsequently a sober and unprejudiced discussion about how
far these phenomena can be accepted should evolve. For fear of
1Radio broadcast in Deutschlandfunk covering the work of a implantation center
in Germany www.dradio.de/dlf/sendungen/forschak/1407092/
putting a well-established and beneficial procedure at peril, its
disadvantages shall not be disguised.
The discussion about target points that carry a lower risk of
changing the patient’s personality should continue. Patients must
be informed about the available targets and the risks and benefits
connected with each of them.
Prerequisite for the future development of DBS are diagnostic
tools that are reliably able to detect the long-term consequences
of the operation on behavior, personality and moral competence.
Suitable scales can be developed or integrated from other
disciplines into the clinical assessment and future studies. These
must concentrate on the crucial domains of social interaction and
judgment of own behavior. They should also address caregivers
and family’s perception of the patient and the impact on their life.
In defense of the procedure a reversal in the argumentation
should be considered:
- The existence of psychiatric side effects as integral part of the
treatment should be conceded.
- It should be asserted that DBS is a reversible therapy and
can therefore not be put on a par with irreversible surgical
interventions like the lesioning of brain areas. In analogy to
drug therapy it can be discontinued simply by switching it off.
- The patient should be fully informed about the intrinsic risks of
psychiatric adverse events, possible changes of personality and
the targets at hand. Ideally the patient’s partners and next of kin
are involved and informed about the possible resulting burden
as caregivers. This will counter the reproach of guiding patients
into a treatment with consequences he cannot foresee.
Clearly the issue of psychiatric side effects of DBS involves
a legally and ethically utterly sophisticated discussion. Yet
postponing it beyond the moment the lay press may cover
negative events in an untoward manner will not improve our
position to influence its already unforeseeable outcome.
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